Serum transaminase elevations as indicators of hepatic injury following the administration of drugs

Regulatory Toxicology and Pharmacology

Volumn 27, Issue 2, 1998, Pages 119-130

  Amacher, David E ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Alanine aminotransferase; Liver injury; Review; Serum transaminases

Indexed keywords

ACARBOSE; ALANINE AMINOTRANSFERASE; AMIODARONE; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BIOCHEMICAL MARKER; CARDIOVASCULAR AGENT; CHLORPROMAZINE; DIURETIC AGENT; IBUFENAC; IPRONIAZID; ISONIAZID; METHYLDOPA; NALTREXONE; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 2; RILUZOLE; TACRINE; TIENILIC ACID; VALPROIC ACID;

AMINOTRANSFERASE BLOOD LEVEL; DRUG DEVELOPMENT; DRUG METABOLISM; DRUG SAFETY; ENZYME INDUCTION; HISTOLOGY; HUMAN; LIVER INJURY; NONHUMAN; PATIENT MONITORING; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

ANIMALIA;

EID: 0031819810     PISSN: 02732300     EISSN: None     Source Type: Journal    
DOI: 10.1006/rtph.1998.1201     Document Type: Article

References (106)

1. Adams L. E., Hess E. V. Drug-related lupus. Incidence, mechanisms and clinical implications. Drug Saf. 6:1991;431-449.
2. Aiges H. W., Daum F., Olson M., Kahn E., Teichberg S. The effects of phenobarbital and diphenylhydantoin on liver function and morphology. J. Pediatr. 97:1980;22-26.
3. Albers R., Broeders A., Van der Pijl A., Seinen W., Pieters R. The use of reporter antigens in the popliteal lymph node assay to assess immunomodulation by chemicals. Toxicol. Appl. Pharmacol. 143:1997;102-109.
4. Anderson N. L., Taylor J., Hoffman J. P., Esquer-Blasco R., Swift S., Anderson N. G. Simultaneous measurement of hundreds of liver proteins: Application in assessment of liver function. Toxicol. Pathol. 24:1996;72-76.
5. Batt A.-M., Ferrari L. Manifestations of chemically induced liver damage. Clin. Chem. 41:1995;1882-1887.
6. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J. Hepatol. 11:1990;272-276.
7. Bigazzi P. E. Autoimmunity induced by chemicals. Clin. Toxicol. 26:1988;125-156.
8. Billon M. C., Dupre G., Hanoune J. In vivo. Mol. Cell. Endocrinol. 18:1980;99-108.
9. 2. Am. J. Med. 83:1987;68-75.
10. Boelsterli U. A., Zimmerman H. J., Kretz-Rommel A. Idiosyncratic liver toxicity of nonsteroidal anti-inflammatory drugs: Molecular mechanisms and pathology. Crit. Rev. Toxicol. 25:1995;207-235.
11. Breckenridge A. A clinical pharmacologist's view of drug toxicity. Br. J. Clin. Pharmacol. 42:1996;53-58.
12. Brockmoller J., Roots I. Assessment of liver metabolic function. Clinical implications. Clin. Pharmacokinet. 27:1994;216-248.
13. Bryson H. M., Fulton B., Benfield P. Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Drugs. 52:1996;549-563.
14. Burns L. A., Meade B. J., Munson A. E. Toxic responses of the immune system. Casarett and Doull's Toxicology. The Basic Science of Poisons. 1996;McGraw-Hill, New York. p. 355-402.
15. Campbell R. D., Milner C. M. MHC genes in autoimmunity. Curr. Opin. Immunol. 5:1993;887-993.
16. Clampitt R. B., Hart R. J. The tissue activities of some diagnostic enzymes in ten mammalian species. J. Comp. Pathol. 88:1978;607-621.
17. Clermont R. J., Chalmers T. C. The transaminase tests in liver disease. Medicine. 46:1967;197-207.
18. Coombs R. R. A., Gell P. G. H. Classification of allergic reactions responsible for clinical hypersensitivity and disease. Gell P. G. H., Coombs R. R. A., Lachmann P. G. Clinical Aspects of Immunology. 1975;761-781 Oxford Univ. Press, Oxford.
19. Craxi A., Almasio P. Diagnostic approach to liver enzyme elevation. J. Hepatol. 25:1996;47-51.
20. Dansette P. M., Amar C., Valadon P., Pons C., Beaune P. H., Mansuy D. Hydroxylation and formation of electrophilic metabolites of tienilic acid and its isomer by human liver microsomes. Biochem. Pharmacol. 41:1991;553-560.
21. Davis M. Drugs and abnormal 'liver function tests.'. Adverse Drug React. Bull. 139:1989;520-523.
22. De Mol N. J., Busker R. W. Irreversible binding of the chlorpromazine radical cation and of photoactivated chlorpromazine to biological macromolecules. Chem.-Biol. Interact. 52:1984;79-92.
23. Dhami M. S. I., Drangova R., Farkas R., Balazs T., Feuer G. Decreased aminotransferase activity of serum and various tissues in the rat after cefazolin treatment. Clin. Chem. 25:1979;1263-1266.
24. Dybing E., Nelson S. D., Mitchell J. R., Sasame H. A., Gillette J. R. Oxidation of α-methyldopa and other catechols by cytochrome P-450-generated superoxide anion: Possible mechanism of methyldopa hepatitis. Mol. Pharmacol. 12:1976;911-920.
25. Ereshefsky L. Drug-drug interactions involving antidepressants: Focus on venlafaxine. J. Clin. Psychopharmacol. 16:1996;37S-53S.
26. Finlayson N. D. The adverse effects of drugs on the liver. Br. J. Clin. Pract. 27:1973;286-290.
27. Foster G. R., Goldin R. D., Oliveira D. B. Serum F protein: A new sensitive and specific test of hepatocellular damage. Clin. Chim. Acta. 184:1989;85-92.
28. Fregia A., Jensen D. M. Evaluation of abnormal liver tests. Comp. Ther. 20:1994;50-54.
29. Fry S. W., Seeff L. B. Hepatotoxicity of analgesics and anti-inflammatory agents. Gastroenterol. Clin. N. Am. 24:1995;875-905.
30. Fronek Z., Timmerman L. A., McDevitt H. O. A rare HLA DQB allele sequenced from patients with systemic lupus erythematosus. Hum. Immunol. 30:1991;77-84.
31. Garcia Rodriguez L. A., Williams R., Derby L. E., Dean A. D., Hershel J. Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch. Intern. Med. 154:1994;311-316.
32. George D. K., Crawford D. H. G. Antibacterial-induced hepatotoxicity. Incidence, prevention, and management. Drug Saf. 15:1996;79-85.
33. Goldstein J. A., de Morais S. M. F. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics. 4:1994;285-299.
34. Grippon P., Hirsch-Marrie I., Biour M., Levy V. G. Drug induced liver disease in a liver unit. A retrospective study of 46 patients in 3 years. Therapie. 39:1984;503-507.
35. Grohmann R., Hippius H., Muller-Oerlinghausen B., Ruther E., Scherer J., Schmidt L. G., Strauss A., Wolf B. Assessment of adverse drug reactions in psychiatric hospitals. Eur. J. Clin. Pharmacol. 26:1984;727-734.
36. Haidukewych D., John G. Chronic valproic acid and coantiepileptic drug therapy and incidence of increases in serum liver enzymes. Ther. Drug Monit. 8:1986;407-410.
37. Helliwell T. R., Yeung J. H. K., Park B. K. Hepatic necrosis and glutathione depletion in captopril-treated mice. Br. J. Exp. Pathol. 66:1985;67-78.
38. Herlong H. F. Approach to the patient with abnormal liver enzymes. Hosp. Pract. 29:1994;32-38.
39. Herzfeld A., Raper S. M. Effects of cortisol or starvation on the activities of four enzymes in small intestine and liver of the rat during development. J. Dev. Physiol. 1:1979;315-327.
40. Hirayanagi N., Fujii E., Teshirogi T. The significance of serum γ-glutamyl transpeptidase (γ-GTP) elevation caused by antiepileptic drug(s). Using the antipyrine metabolic capacity as a parameter of microsomal enzyme activity. Nippon Ika Daigaku Zasshi. 58:1991;547-560.
41. Hodgson M. J., Van Thiel D. H., Lauschus K., Karpf M. Liver injury tests in hazardous waste workers: The role of obesity. J. Occup. Med. 31:1989;238-242.
42. Hoffmann W. E., Kramer J., Main A. R., Torres J. L. Clinical enzymology. Loeb W. F., Quimby F. W. The Clinical Chemistry of Laboratory Animals. 1989;237-278 Pergamon Press, New York.
43. Hultcrantz R., Glaumann H., Lindberg G., Son Nilsson L. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. Scand. J. Gastroenterol. 21:1986;109-113.
44. Iwatsubo T., Hirota N., Ooie T., Suzuki H., Shimada N., Chiba K., Ishizaki T., Green C. E., Tyson C. A., Sugiyama Y. Prediction ofin vivoin vitro. Pharmacol. Ther. 73:1997;147-171.
45. Jacobsen N. O., Mosekilde L., Myhre-Jensen O., Pedersen E., Wildenhoff K. E. Liver biopsies in epileptics during anticonvulsant therapy. Acta Med. Scand. 199:1976;345-348.
46. Jean-Pastor M. J., Jouglard J. Bilan des accidents hepatiques medicamenteux recueillis par la pharmacovigilance francaise. Therapie. 39:1984;493-500.
47. Jick H. Drug-associated asymptomatic elevations of transaminase in drug safety assessments. Pharmacotherapy. 15:1995;23-25.
48. Jurima-Romet M., Huang H. S. Enalapril hepatotoxicity in the rat. Effects of modulators of cytochrome P450 and glutathione. Biochem. Pharmacol. 44:1992;1803-1810.
49. King P. D., Perry M. C. Hepatotoxicity of chemotherapeutic and oncologic agents. Gastroenterol. Clin. N. Am. 24:1995;969-990.
50. Koch-Weser J., Browne T. R. Drug therapy: Valproic acid. New Engl. J. Med. 302:1980;661-666.
51. Lam K. S. Application of combinatorial library methods in cancer research and drug discovery. Anticancer Drug Des. 12:1997;145-167.
52. Larrey D., Pageaux G. P. Genetic predisposition to drug-induced hepatotoxicity. J. Hepatol. 26:1997;12-21.
53. LeCluyse E. L., Audus K. L., Hochman J. H. Formation of extensive canalicular networks by rat hepatocytes cultured in collagen-sandwich configuration. Am. J. Physiol. 266:1994;C1764-C1774.
54. Lewis J. H. Hepatic toxicity of nonsteroidal anti-inflammatory drugs. Clin. Pharm. 3:1984;128-138.
55. Lewis J. H., Ranard R. C., Caruso A., Jackson L. K., Mullick F., Ishak K. G., Seeff L. B., Zimmerman H. J. Amiodarone hepatotoxicity: Prevalence and clinicopathologic correlations among 104 patients. Hepatology. 9:1989;679-685.
56. McDonald G. B., Tirumali N. Intestinal and liver toxicity of antineoplastic drugs. West. J. Med. 140:1984;250-259.
57. Meyer U. A. Overview of enzymes of drug metabolism. J. Pharmacokinet. Biopharm. 24:1996;449-459.
58. Meyer U. A., Zanger U. M. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu. Rev. Pharmacol. Toxicol. 37:1997;269-296.
59. Mijovic V., Contreras M., Barbara J. Serum alanine aminotransferase (ALT) and γ-glutamyltransferase (γ-GT) activities in north London blood donors. J. Clin. Pathol. 40:1987;1340-1344.
60. Miyamoto G., Zahid N., Uetrecht J. P. Oxidation of diclofenac to reactive intermediates by neutrophils, myeloperoxidase, and hypochlorous acid. Chem. Res. Toxicol. 10:1997;414-419.
61. Morgan M. Y., Reshef R., Shah R. R., Oates N. S., Smith R. L., Sherlock S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut. 25:1984;1057-1064.
62. Mosca P., Bonazzi P., Novelli G., Jezequel A. M., Orlandi F. In vivoin vitro. Br. J. Exp. Pathol. 66:1985;737-742.
63. Moslen M. T. Toxic responses of the liver. Klaassen C. D. Casarett and Doull's Toxicology. The Basic Science of Poisons. 1996;403-416 McGraw-Hill, New York.
64. Nishimura M., Stein H., Berges W., Teschke R. Gamma-glutamyltransferase activity in the liver plasma membrane: Induction following chronic alcohol consumption. Biochem. Biophys. Res. Commun. 99:1981;141-148.
65. Pappas N. J. Jr. Source of increased serum aspartate and alanine aminotransferase: Cycloheximide effect on carbon tetrachloride hepatotoxicity. Clin. Chim. Acta. 154:1986;181-190.
66. Park B. K., Pirmohamed M., Kitteringham N. R. Idiosyncratic drug reactions: A mechanistic evaluation of risk factors. Br. J. Clin. Pharmacol. 34:1992;377-395.
67. Pessayre D. III. Mechanisms of drug-induced hepatic injury. Stricker B. H. Ch. Drug Induced Hepatic Injury. 1992;23-49 Elsevier, New York.
68. Pirmohamed M., Kitteringham N. R., Park B. K. Idiosyncratric reactions to antidepressants: A review of possible mechanisms and predisposing factors. Pharmacol. Ther. 53:1992;105-125.
69. Pirmohamed M., Madden S., Park B. K. Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism. Clin. Pharmacokinet. 31:1996;215-230.
70. Porubek D. J., Grillo M. P., Baillie T. A. The covalent binding to protein of valproic acid and its hepatotoxic metabolite, 2-n. Drug Metab. Dispos. 17:1989;123-130.
71. Pumford N. R., Halmes N. C. Protein targets of xenobiotic reactive intermediates. Annu. Rev. Pharmacol. Toxicol. 37:1997;91-117.
72. Pumford N. R., Halmes N. C., Hinson J. A. Covalent binding of xenobiotics to specific proteins in the liver. Drug Metab. Rev. 29:1997;39-57.
73. Rahmat J., Gelfand R. L., Gelfand M. C., Winchester J. F., Schreiner G. E., Zimmerman H. J. Captopril-associated cholestatic jaundice. Ann. Intern. Med. 102:1985;56-58.
74. Rej R. Aminotransferases in disease. Diagn. Enzymol. 9:1989;667-687.
75. Renner E. L., Dallenbach A. Erhohte leberenzyme: Was nun? Ther. Umsch. 49:1992;281-286.
76. Richardson F. C., Horn D. M., Anderson N. L. Dose-responses in rat hepatic protein modification and expression following exposure to the rat hepatocarcinogen methapyrilene. Carcinogenesis. 15:1994;325-329.
77. Runge-Morris M. A. Regulation of expression of the rodent cytosolic sulfotransferases. FASEB J. 11:1997;109-117.
78. Sakagishi Y. Alanine aminotransferase (ALT). Nippon Rinsho. 53:1995;1146-1150.
79. Sameshima Y., Shiozaki Y., Mizuno T., Sasakawa M. Drug-induced hepatic injury. Jpn. J. Gastroenterol. 81:1984;37-45.
80. Scheig R. Evaluation of test used to screen patients with liver disorders. Primary care. Clin. Office Prac. 23:1996;551-560.
81. Schiaffonati L., Tiberio L. Gene expression in liver after toxic injury: Analysis of heat shock response and oxidative stress-inducible genes. Liver. 17:1997;183-191.
82. Schmidt E., Schmidt F. W. Progress in the enzyme diagnosis of liver disease: Reality or illusion? Clin. Biochem. 23:1990;375-382.
83. Sherman K. E. Alanine aminotransferase in clinical practice. A review. Arch. Intern. Med. 151:1991;260-265.
84. Spina E., Campo G. M., Avenoso A., Caputi A. P., Zuccaro P., Pacifici R., Gatti G., Strada G., Bartoli A., Perucca E. CYP2D6-related oxidation polymorphism in Italy. Pharmacol. Res. 29:1994;281-289.
85. Stricker B. H. Ch. Hepatic injury by drugs and environmental agents. Arias I. M., Frenkel M., Wilson J. H. P. The Liver Annual. 1986;419-482 Elsevier, New York.
86. Stricker B. H. Ch., Blok A. P. R., Desmot V. J. IV. Pathology of drug-induced hepatic injury. Stricker B. H. Ch. Drug-Induced Hepatic Injury. 1992a;51-70 Elsevier, New York.
87. Stricker B. H. Ch., Biour M., Wilson J. H. P. V. Individual agents: Drugs. Stricker B. H. Ch. Drug-Induced Hepatic Injury. 1992b;71-524 Elsevier, New York.
88. Tabibian N., Alpert L., Alpert E. Captopril-induced liver dysfunction. South. Med. J. 80:1987;1173-1175.
89. Teschke R., Neuefeind M., Nishimura M., Strohmeyer G. Hepatic gamma-glutamyltransferase activity in alcoholic fatty liver: Comparison with other liver enzymes in man and rats. Gut. 24:1983;625-630.
90. Timbrell J. A., Mitchell J. R., Snodgrass W. R., Nelson S. D. Isoniazid hepatotoxicity: The relationship between covalent binding and metabolismin vivo. J. Pharmacol. Exp. Ther. 213:1980;364-369.
91. Uetrecht J. P. Mechanism of drug-induced lupus. Chem. Res. Toxicol. 1:1988;133-143.
92. Ulrich R. G., Bacon J. A., Cramer C. T., Peng G. W., Petrella D. K., Stryd R. P., Sun E. L. Cultured hepatocytes as investigational models for hepatic toxicity: Practical applications in drug discovery and development. Toxicol. Lett. 82/83:1995;107-115.
93. Van Dijke C. P. H., Mattie E. N. H. Bijwerkingen van geneesmiddelen op een afdeling inwendige geneeskunde. Ned. Tijdschr. Geneeskd. 130:1986;1889-1893.
94. Wall M., Baird-Lambert J., Buchanan N., Farrell G. Liver function tests in persons receiving anticonvulsant medications. Seizure. 1:1992;187-190.
95. Waner T., Nyska A. The toxicological significance of decreased activities of blood alanine and aspartate aminotransferase. Vet. Res. Commun. 15:1991;73-78.
96. Watkins P. B. Role of cytochromes P450 in drug metabolism and hepatotoxicity. Semin. Liver Dis. 10:1990;235-250.
97. Watkins P. B., Zimmerman H. J., Knapp M. J., Gracon S. I., Lewis K. W. Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. JAMA. 271:1994;992-998.
98. Westphal J. F., Vetter D., Brogard J. M. Hepatic side effects of antibiotics. J. Antimicrob. Chemother. 33:1994;387-401.
99. Wilkinson G. R. Cytochrome P4503A (CYP3A) metabolism: Prediction ofin vivo. J. Pharmacokinet. Biopharm. 24:1996;475-490.
100. Wright C., Rivera J. C., Baetz J. H. Liver function testing in a working population: Three strategies to reduce false-positive results. J. Occup. Med. 30:1988;693-697.
101. Yamada R. H., Wakabayahsi Y., Iwashima A. Inhibition of serum aspartate aminotransferase induced by isoniazid administration in mice. Acta Vitaminol. Enzymol. 6:1984a;289-294.
102. Yamada R., Wakabayahsi Y., Iwashima A. "In vivo. Acta Vitaminol. Enzymol. 6:1984b;29-39.
103. Zeisel S. H., Da Costa K.-A., Franklin P. D., Alexander E. A., Lamont J. T., Sheard N. F., Beiser A. Choline, an essential nutrient for humans. FASEB J. 5:1991;2093-2098.
104. Zimmerman H. J. Function and integrity of the liver. Henry J. B. Clinical Diagnosis and Management by Laboratory Methods. 1984;217-250 Saunders, Philadelphia.
105. Zimmerman H. J. Editorial: Aspirin-induced hepatic injury. Ann. Intern. Med. 80:1974;103-105.
106. Zimmerman H. J. Hepatotoxicity. The Adverse Effects of Drugs and Other Chemicals on the Liver. 1978;Appleton-Century-Crofts, New York.